Number of		Percent with outcome
Outcome - daily dose	Studies	Participants	Pregabalin	Placebo	Relative benefit (95% CI)	NNT (95% CI)
At least 30% pain relief
150 mg	no data
300 mg	2	482	59	45	1.3 (1.1 to 1.6)	6.8 (4.3 to 17)
300 mg (≥ 8 weeks)	1	304	58	52	1.1 (0.9 to 1.4)	not calculated
600 mg	3	819	63	43	1.5 (1.3 to 1.7)	5.1 (3.8 to 7.8)
600 mg (≥ 8 weeks)	2	641	62	48	1.3 (1.1 to 1.5)	6.8 (4.4 to 15)
At least 50% pain relief
150 mg	2	359	27	23	1.1 (0.8 to 1.6)	not calculated
150 mg (≥ 8 weeks)	1	195	34	30	1.1 (0.8 to 1.7)	not calculated
300 mg	4	823	40	26	1.5 (1.2 to 1.8)	7.5 (5.1 to 14)
300 mg (≥ 8 weeks)	3	645	38	29	1.3 (1.1 to 1.6)	11 (6.1 to 54)
600 mg	6	1360	45	25	1.7 (1.5 to 2.0)	5.0 (4.0 to 6.6)
600 mg (≥ 8 weeks)	4	1005	46	30	1.5 (1.3 to 1.8)	6.3 (4.6 to 10)
PGIC much or very much improved
150 mg	1	195	45	34	1.4 (0.96 to 2.0)	not calculated
300 mg	2	359	48	30	1.6 (1.2 to 2.1)	5.6 (3.6 to 13)
300 mg (≥ 8 weeks)	1	195	42	33	1.3 (0.9 to 1.8)	not calculated
600 mg	4	875	56	33	1.8 (1.5 to 2.1)	4.2 (3.3 to 5.8)
600 mg (≥ 8 weeks)	3	702	54	36	1.5 (1.3 to 1.8)	5.4 (3.9 to 9.2)
Lack of efficacy discontinuation						NNTp (95% CI)
150 mg	2	359	4	7	0.7 (0.3 to 1.5)	not calculated
150 mg (≥ 8 weeks)	1	195	8	11	0.7 (0.3 to 1.7)	not calculated
300 mg	2	341	3	8	0.4 (0.2 to 1.0)	not calculated
600 mg	4	869	4	11	0.3 (0.2 to 0.5)	14 (9 to 31)
600 mg (≥ 8 weeks)	3	702	4	14	0.3 (0.2 to 0.5)	10 (6.9 to 20)